IVERIC bio Inc ISEE:NASDAQ

Last Price$11.06NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$11.06 (11)
Ask (Size)$11.07 (228)
Day Low / HighN/A - N/A
Volume1.9 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022

 

IVERIC bio Inc ( NASDAQ )

Price: $11.06
Change: +0.23 (2.12%)
Volume: 1.9 M
4:00PM ET 5/20/2022
 
 

Veracyte Inc ( NASDAQ )

Price: $18.37
Change: +0.90 (5.15%)
Volume: 1.1 M
4:00PM ET 5/20/2022
 
 

Pacific Biosciences of California Inc ( NASDAQ )

Price: $5.61
Change: +0.01 (0.18%)
Volume: 8.1 M
4:00PM ET 5/20/2022
 
 

Arcus Biosciences Inc ( NYSE )

Price: $18.92
Change: +0.42 (2.27%)
Volume: 1.0 M
7:00PM ET 5/20/2022
 
 

Celldex Therapeutics Inc ( NASDAQ )

Price: $29.16
Change: +0.24 (0.83%)
Volume: 530.4 K
4:00PM ET 5/20/2022
 

Read more news Recent News

--B. Riley Initiates IVERIC bio at Neutral with $12 Price Target, Says Taking 'Wait and See' Approach Until Picture Is Clearer
10:35AM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Stifel Adjusts IVERIC Bio's Price Target to $28 From $22, Reiterates Buy Rating
5:15AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Sell: Iveric Bio
5:37PM ET 4/20/2022 MT Newswires

Keith Westby, Senior Vice President & COO, on April 18, 2022, sold 10,000 shares in Iveric Bio (ISEE) for $166,300. Following the Form 4 filing with the...

IVERIC bio Shares Rise After Jefferies Starts Coverage at Buy
1:00PM ET 3/22/2022 MT Newswires

IVERIC bio (ISEE) shares were up more than 6.0% in Tuesday afternoon trading after Jefferies started coverage on the stock with a buy rating and a $27...

Company Profile

Business DescriptionIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. View company web site for more details
Address8 Sylvan Way
Parsippany, New Jersey 07054
Phone+1.609.474.6755
Number of Employees35
Recent SEC Filing05/18/20228-K
Chief Executive Officer & DirectorGlenn P. Sblendorio
PresidentPravin U. Dugel
Chief Operating Officer & Senior Vice PresidentKeith Westby
Chief Financial Officer, Treasurer & Senior VPDavid F. Carroll

Company Highlights

Price Open$11.08
Previous Close$10.83
52 Week Range$5.72 - 19.35
Market Capitalization$1.3 B
Shares Outstanding116.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.13
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-46.15%

Analyst Ratings as of 05/10/2022

Buy
7
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset